Quanterix Co. (NASDAQ:QTRX) to Post FY2026 Earnings of ($0.83) Per Share, Leerink Partnrs Forecasts

Quanterix Co. (NASDAQ:QTRX) – Equities research analysts at Leerink Partnrs issued their FY2026 earnings per share estimates for Quanterix in a research report issued on Thursday, August 8th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings of ($0.83) per share for the year. The consensus estimate for Quanterix’s current full-year earnings is ($0.87) per share.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Quanterix had a negative return on equity of 10.39% and a negative net margin of 28.82%. The firm had revenue of $34.38 million during the quarter, compared to analyst estimates of $34.19 million. During the same quarter last year, the firm posted ($0.16) EPS.

Other equities research analysts have also recently issued research reports about the company. The Goldman Sachs Group decreased their target price on Quanterix from $35.00 to $24.00 and set a “buy” rating for the company in a research note on Tuesday, July 9th. TD Cowen lowered their price objective on shares of Quanterix from $17.00 to $15.00 and set a “hold” rating for the company in a research note on Friday, August 9th. Canaccord Genuity Group cut their target price on shares of Quanterix from $32.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday, April 29th. Finally, Scotiabank decreased their price target on shares of Quanterix from $32.00 to $28.00 and set a “sector outperform” rating for the company in a research note on Monday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Quanterix presently has a consensus rating of “Moderate Buy” and an average target price of $24.80.

Quanterix Stock Down 1.2 %

QTRX stock opened at $11.14 on Monday. The firm has a market cap of $426.33 million, a price-to-earnings ratio of -11.60 and a beta of 1.39. The company’s fifty day simple moving average is $14.03 and its 200 day simple moving average is $18.65. Quanterix has a 12-month low of $10.50 and a 12-month high of $29.70.

Institutional Investors Weigh In On Quanterix

Hedge funds and other institutional investors have recently modified their holdings of the company. Strs Ohio grew its position in Quanterix by 5.7% in the 4th quarter. Strs Ohio now owns 18,400 shares of the company’s stock valued at $503,000 after purchasing an additional 1,000 shares during the period. Semanteon Capital Management LP bought a new stake in shares of Quanterix during the fourth quarter worth about $971,000. Truist Financial Corp acquired a new stake in shares of Quanterix in the 4th quarter worth about $419,000. Valmark Advisers Inc. lifted its position in Quanterix by 3.5% in the 4th quarter. Valmark Advisers Inc. now owns 69,736 shares of the company’s stock valued at $1,907,000 after acquiring an additional 2,363 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Quanterix by 17.4% during the 4th quarter. Russell Investments Group Ltd. now owns 20,046 shares of the company’s stock valued at $548,000 after purchasing an additional 2,973 shares during the last quarter. Institutional investors own 86.48% of the company’s stock.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.